Drugs in Dev. Urology
Phase I
Vensica Medical Secures $11M for Overactive Bladder Phase 2 Trials
Details : The fund will support the company's mid-stage clinical trials for its revolutionary treatment of overactive bladder using Xeomin (Incobotulinumtoxin A), delivered through a needle-free device.
Brand Name : Xeomin
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 28, 2024
Details : GLX-100 is a novel biopolymer, which has been designed to closely replicate the natural protective barrier layer and relieve the symptoms of Interstitial Cystitis/Bladder Pain Syndrome and Phase I results anticipated in 2024.
Brand Name : GLX-100
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 24, 2023
Details : IMB-150 (also known as LYT-503) as a potential non-opioid treatment for female patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). IMB-150, is a novel formulation of lidocaine, and the clinical development program is called GainMe-IC.
Brand Name : LYT-503
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 20, 2022
Details : To investigate safety and feasibility of a tissue-regenerative approach to treat stress urinary incontinence (SUI) in female patients with a novel transurethral injection therapy using autologous MPCs in a combination with NMES.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 08, 2022
LOOKING FOR A SUPPLIER?
Reset All
